SDIC Securities released a research report on April 11 stating that Maiwei Biotech (688062.SH) was given a purchase rating and the target price was 47.95 yuan. The main reasons for the rating include: 1) Overseas licensing of NECTIN-4 ADC is worth looking forward to; B7H3 ADC and TROP2 ADC are progressing smoothly; 2) Long-acting whitening drugs are expected to be approved for marketing in 2025, and domestic and overseas markets for many biosimilar drugs are actively expanding. (Mainichi Keizai Shimbun)
国投证券4月11日发布研报称，给予迈威生物（688062.SH）买入评级，目标价格为47.95元。评级理由主要包括：1）NECTIN-4 ADC 海外授权值得期待，B7H3 ADC、TROP2 ADC 临床顺利推进中；2）长效升白药有望于 2025 年获批上市，多个生物类似药国内及海外市场积极拓展中。（每日经济新闻）
SDIC Securities released a research report on April 11 stating that Maiwei Biotech (688062.SH) was given a purchase rating and the target price was 47.95 yuan. The main reasons for the rating include: 1) Overseas licensing of NECTIN-4 ADC is worth looking
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated